Posted by Michael Wonder on 25 Oct 2019
Proposal to award sole supply for apomorphine hydrochloride
25 October 2019 - PHARMAC is proposing to make changes to the funding of apomorphine hydrochloride, a medicine used to treat advanced Parkinson’s disease, through an agreement with Stada.
In summary:
- The Movapo brand of apomorphine hydrochloride 20 mg/2 mL ampoule would remain funded
- A new apomorphine hydrochloride 50 mg/5 mL ampoule would be funded from 1 February 2020
